{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:13:54Z","timestamp":1793938434228,"version":"4.8.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"am","delay-in-days":320,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ajo.2024.08.044","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T02:13:51Z","timestamp":1726107231000},"page":"348-359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Ophthalmic Immune-Related Adverse Events and Association with Survival: Results From a Real-World Database"],"prefix":"10.1016","volume":"268","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4518-6780","authenticated-orcid":false,"given":"Lee","family":"Quiruz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9914-2935","authenticated-orcid":false,"given":"Negin","family":"Yavari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijal","family":"Kikani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8443-5519","authenticated-orcid":false,"given":"Ankur Sudhir","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen Michelle","family":"Wai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3110-1210","authenticated-orcid":false,"given":"Andrea Lora","family":"Kossler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9586-3735","authenticated-orcid":false,"given":"Chase","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eubee Baughn","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Rahimy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1087-9736","authenticated-orcid":false,"given":"Prithvi","family":"Mruthyunjaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2024.08.044_bib0001","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jtos.2021.02.004","article-title":"Ocular surface disease associated with immune checkpoint inhibitor therapy","volume":"20","author":"Park","year":"2021","journal-title":"Ocular Surf"},{"issue":"17","key":"10.1016\/j.ajo.2024.08.044_bib0002","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J clin Oncol"},{"issue":"6","key":"10.1016\/j.ajo.2024.08.044_bib0003","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","article-title":"Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects","volume":"38","author":"Dalvin","year":"2018","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.ajo.2024.08.044_bib0004","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/01676830.2020.1867192","article-title":"Ophthalmic complications of immune checkpoint inhibitors","volume":"41","author":"Wladis","year":"2022","journal-title":"Orbit"},{"key":"10.1016\/j.ajo.2024.08.044_bib0005","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.2147\/DDDT.S267433","article-title":"Research status and outlook of PD-1\/PD-L1 inhibitors for cancer therapy","author":"Ai","year":"2020","journal-title":"Drug Design, Develop Ther"},{"issue":"1","key":"10.1016\/j.ajo.2024.08.044_bib0006","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12348-022-00321-2","article-title":"Ocular adverse events associated with immune checkpoint inhibitors, a scoping review","volume":"13","author":"Martens","year":"2023","journal-title":"J Ophthal Inflammation Infect"},{"issue":"4","key":"10.1016\/j.ajo.2024.08.044_bib0007","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14737140.2017.1296765","article-title":"Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review","volume":"17","author":"Abdel-Rahman","year":"2017","journal-title":"Expert review of anticancer therapy"},{"issue":"4","key":"10.1016\/j.ajo.2024.08.044_bib0008","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jamaoncol.2019.5570","article-title":"Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial","volume":"6","author":"Eggermont","year":"2020","journal-title":"JAMA oncol"},{"issue":"2","key":"10.1016\/j.ajo.2024.08.044_bib0009","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jamadermatol.2021.5476","article-title":"Association of cutaneous immune-related adverse events with increased survival in patients treated with anti\u2013programmed cell death 1 and anti\u2013programmed cell death Ligand 1 therapy","volume":"158","author":"Tang","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.ajo.2024.08.044_bib0010","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/CCO.0000000000000296","article-title":"Ocular and orbital side-effects of checkpoint inhibitors: a review article","volume":"28","author":"Antoun","year":"2016","journal-title":"Curr Opin Oncol"},{"issue":"1","key":"10.1016\/j.ajo.2024.08.044_bib0011","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/09273948.2020.1773867","article-title":"Ocular adverse events induced by immune checkpoint inhibitors: a comprehensive pharmacovigilance analysis","volume":"30","author":"Bomze","year":"2022","journal-title":"Ocular Immunol Inflammation"},{"issue":"9","key":"10.1016\/j.ajo.2024.08.044_bib0012","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1136\/bjophthalmol-2020-316970","article-title":"Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience","volume":"105","author":"Fortes","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2024.08.044_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1302293","article-title":"Association between immune checkpoint inhibitor medication and uveitis: a population-based cohort study utilizing TriNetX database","volume":"14","author":"Kuo","year":"2024","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.ajo.2024.08.044_bib0014","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ophtha.2023.10.004","article-title":"Drug-induced uveitis related to checkpoint inhibitors and MAP-kinase inhibitors","volume":"131","author":"Thibault","year":"2023","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2024.08.044_bib0015","doi-asserted-by":"crossref","first-page":"98","DOI":"10.36401\/JIPO-22-14","article-title":"Highlights on ocular toxicity of immune checkpoint inhibitors at a US tertiary cancer center","volume":"5","author":"Mazharuddin","year":"2022","journal-title":"J Immunother Prec Oncol"},{"key":"10.1016\/j.ajo.2024.08.044_bib0016","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ajo.2020.12.013","article-title":"Population-based frequency of ophthalmic adverse events in melanoma, other cancers, and after immune checkpoint inhibitor treatment","volume":"224","author":"Braun","year":"2021","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2024.08.044_bib0020","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.ophtha.2019.01.031","article-title":"Ophthalmic immune-related adverse events of immunotherapy: a single-site case series","volume":"126","author":"Kim","year":"2019","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2024.08.044_bib0021","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.joco.2019.05.002","article-title":"Ocular adverse events with immune checkpoint inhibitors","volume":"31","author":"Fang","year":"2019","journal-title":"J Curr Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2024.08.044_bib0022","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1080\/09273948.2021.1890133","article-title":"Risk of ophthalmic adverse events in patients treated with immune checkpoint inhibitor regimens: A systematic review and meta-analysis","volume":"30","author":"Hou","year":"2022","journal-title":"Ocular Immunol Inflammation"},{"key":"10.1016\/j.ajo.2024.08.044_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1130238","article-title":"Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors","volume":"14","author":"Gan","year":"2023","journal-title":"Front Immunol"},{"issue":"17","key":"10.1016\/j.ajo.2024.08.044_bib0024","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.3390\/jcm11174993","article-title":"Ocular inflammation induced by immune checkpoint inhibitors","volume":"11","author":"Chaudot","year":"2022","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.ajo.2024.08.044_bib0025","doi-asserted-by":"crossref","first-page":"646","DOI":"10.18240\/ijo.2022.04.19","article-title":"Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management","volume":"15","author":"Zhou","year":"2022","journal-title":"Int J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2024.08.044_bib0026","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.ophtha.2020.11.001","article-title":"Ophthalmic immune-related adverse events after anti-CTLA-4 or PD-1 therapy recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry","volume":"128","author":"Sun","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2024.08.044_bib0027","article-title":"Ocular immune-related adverse events associated with immune checkpoint inhibitors in lung cancer","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ajo.2024.08.044_bib0028","first-page":"857519","article-title":"Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management","volume":"2013","author":"Tarhini","year":"2013","journal-title":"Scientifica"},{"key":"10.1016\/j.ajo.2024.08.044_bib0029","doi-asserted-by":"crossref","first-page":"1137637","DOI":"10.3389\/ftox.2023.1137637","article-title":"Ocular surface complications following biological therapy for cancer","volume":"5","author":"Ma","year":"2023","journal-title":"Front Toxicol"},{"issue":"11","key":"10.1016\/j.ajo.2024.08.044_bib0030","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.3390\/ijms21113962","article-title":"Immune checkpoints contribute corneal immune privilege: implications for dry eye associated with checkpoint inhibitors","volume":"21","author":"Hori","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.ajo.2024.08.044_bib0031","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.survophthal.2023.10.002","article-title":"Ocular surface toxicities associated with modern anticancer therapies","volume":"69","author":"Boucher","year":"2023","journal-title":"Survey Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2024.08.044_bib0032","first-page":"382","article-title":"Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer","volume":"36","author":"Le","year":"2013","journal-title":"J Immunother (Hagerstown, Md: 1997)"},{"issue":"4","key":"10.1016\/j.ajo.2024.08.044_bib0033","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1158\/1078-0432.CCR-10-2463","article-title":"Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc\/IV melanoma","volume":"17","author":"Sarnaik","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ajo.2024.08.044_bib0034","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/1759-7714.13327","article-title":"Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy","volume":"11","author":"Liu","year":"2020","journal-title":"Thoracic Cancer"},{"issue":"2","key":"10.1016\/j.ajo.2024.08.044_bib0035","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.ajo.2024.08.044_bib0036","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.ophtha.2024.03.017","article-title":"Incident non-infectious uveitis risk after immune checkpoint inhibitor treatment","volume":"131","author":"Chang","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2024.08.044_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fopht.2022.1044904","article-title":"Neuro-ophthalmic complications of immune checkpoint inhibitor therapy: current status and future directions","volume":"2","author":"Winges","year":"2022","journal-title":"Front Ophthal"},{"issue":"7","key":"10.1016\/j.ajo.2024.08.044_bib0038","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/00207454.2020.1831489","article-title":"Isolated optic neuritis after pembrolizumab administration for non-small-cell lung carcinoma","volume":"132","author":"Makri","year":"2022","journal-title":"Int J Neurosci"},{"issue":"8","key":"10.1016\/j.ajo.2024.08.044_bib0039","first-page":"333","article-title":"Myasthenia gravis induced by inmuno checkpoints inhibitors: first case report secondary to avelumab therapy and review of published cases","volume":"68","author":"Reyes-Bueno","year":"2019","journal-title":"Revista de Neurologia"},{"issue":"4","key":"10.1016\/j.ajo.2024.08.044_bib0040","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/j.cllc.2019.04.007","article-title":"Immune checkpoint inhibitor-induced myasthenia gravis in a patient with advanced NSCLC and remote history of thymoma","volume":"20","author":"Lara","year":"2019","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"10.1016\/j.ajo.2024.08.044_bib0041","first-page":"140","article-title":"Ipilimumab-induced ocular and orbital inflammation\u2014a case series and review of the literature","volume":"24","author":"Papavasileiou","year":"2016","journal-title":"Ocular Immunol Inflamm"},{"issue":"25","key":"10.1016\/j.ajo.2024.08.044_bib0042","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti\u2013cytotoxic T-lymphocyte antigen-4","volume":"23","author":"Attia","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939424004161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939424004161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T12:29:25Z","timestamp":1732624165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939424004161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":39,"alternative-id":["S0002939424004161"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2024.08.044","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ophthalmic Immune-Related Adverse Events and Association with Survival: Results From a Real-World Database","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2024.08.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}